CVAC Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of -5832.47% compared to CureVac NV's net margin of -227.46%. CureVac NV's return on equity of 32.68% beat BioNTech SE's return on equity of -3.91%.

CureVac NV has a consensus price target of $5.92, signalling upside risk potential of 8.84%. On the other hand BioNTech SE has an analysts' consensus of $135.60 which suggests that it could grow by 29.39%. Given that BioNTech SE has higher upside potential than CureVac NV, analysts believe BioNTech SE is more attractive than CureVac NV.

CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.759%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

CureVac NV quarterly revenues are $939.6K, which are smaller than BioNTech SE quarterly revenues of $192.3M. CureVac NV's net income of -$54.8M is higher than BioNTech SE's net income of -$437.5M. Notably, CureVac NV's price-to-earnings ratio is 6.02x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 2.13x versus 8.50x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Fresenius Medical Care AG has a net margin of -5832.47% compared to CureVac NV's net margin of 3.1%. CureVac NV's return on equity of 32.68% beat Fresenius Medical Care AG's return on equity of 4.05%.

CureVac NV has a consensus price target of $5.92, signalling upside risk potential of 8.84%. On the other hand Fresenius Medical Care AG has an analysts' consensus of $31.05 which suggests that it could grow by 11.96%. Given that Fresenius Medical Care AG has higher upside potential than CureVac NV, analysts believe Fresenius Medical Care AG is more attractive than CureVac NV.

CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fresenius Medical Care AG has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.825%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fresenius Medical Care AG offers a yield of 2.94% to investors and pays a quarterly dividend of $0.81 per share. CureVac NV pays -- of its earnings as a dividend. Fresenius Medical Care AG pays out 64.91% of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CureVac NV quarterly revenues are $939.6K, which are smaller than Fresenius Medical Care AG quarterly revenues of $5.1B. CureVac NV's net income of -$54.8M is lower than Fresenius Medical Care AG's net income of $159.1M. Notably, CureVac NV's price-to-earnings ratio is 6.02x while Fresenius Medical Care AG's PE ratio is 24.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 2.13x versus 0.78x for Fresenius Medical Care AG. Usually stocks with elevated PS ratios are considered overvalued.

Merck KGaA has a net margin of -5832.47% compared to CureVac NV's net margin of 13.92%. CureVac NV's return on equity of 32.68% beat Merck KGaA's return on equity of 9.69%.

CureVac NV has a consensus price target of $5.92, signalling upside risk potential of 8.84%. On the other hand Merck KGaA has an analysts' consensus of $35.10 which suggests that it could grow by 35.68%. Given that Merck KGaA has higher upside potential than CureVac NV, analysts believe Merck KGaA is more attractive than CureVac NV.

CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck KGaA has a beta of 0.957, suggesting its less volatile than the S&P 500 by 4.302%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck KGaA offers a yield of 1.93% to investors and pays a quarterly dividend of $0.50 per share. CureVac NV pays -- of its earnings as a dividend. Merck KGaA pays out 10.23% of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CureVac NV quarterly revenues are $939.6K, which are smaller than Merck KGaA quarterly revenues of $5.6B. CureVac NV's net income of -$54.8M is lower than Merck KGaA's net income of $773.4M. Notably, CureVac NV's price-to-earnings ratio is 6.02x while Merck KGaA's PE ratio is 18.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 2.13x versus 2.46x for Merck KGaA. Usually stocks with elevated PS ratios are considered overvalued.

Siemens Healthineers AG has a net margin of -5832.47% compared to CureVac NV's net margin of 8.97%. CureVac NV's return on equity of 32.68% beat Siemens Healthineers AG's return on equity of 11.11%.

CureVac NV has a consensus price target of $5.92, signalling upside risk potential of 8.84%. On the other hand Siemens Healthineers AG has an analysts' consensus of -- which suggests that it could fall by --. Given that CureVac NV has higher upside potential than Siemens Healthineers AG, analysts believe CureVac NV is more attractive than Siemens Healthineers AG.

CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Siemens Healthineers AG has a beta of 0.996, suggesting its less volatile than the S&P 500 by 0.38%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Siemens Healthineers AG offers a yield of 3.67% to investors and pays a quarterly dividend of $0.50 per share. CureVac NV pays -- of its earnings as a dividend. Siemens Healthineers AG pays out 54.74% of its earnings as a dividend. Siemens Healthineers AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CureVac NV quarterly revenues are $939.6K, which are smaller than Siemens Healthineers AG quarterly revenues of $6.2B. CureVac NV's net income of -$54.8M is lower than Siemens Healthineers AG's net income of $557.7M. Notably, CureVac NV's price-to-earnings ratio is 6.02x while Siemens Healthineers AG's PE ratio is 27.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 2.13x versus 2.47x for Siemens Healthineers AG. Usually stocks with elevated PS ratios are considered overvalued.